|
|
|
 |
Search published articles |
 |
|
Showing 3 results for Chronic
A Ghaziasadi , M Ziai , M Norouzi , R Malekzadeh , Sm Alavian , M Judaki , S Ghamari , A Khedive , A Namazi , Sm Jazayeri ,
Volume 5, Issue 2 (5-2011)
Abstract
Background and Aims: The aim of this study was to determine the correlation between the hepatitis B virus surface Ag (HBsAg) genotypes and variations in the clinical/serological pictures among HBsAg positive chronic patients from South Khorasan province of Iran. Methods: Twenty-five patients were enrolled in this study. The HBs Ag gene was amplified and was directly sequenced. Genotypes and nucleotide/amino acid substitutions were characterized comparing with sequences obtained from the database. Results: All strains belonged to genotype D, subgenotype D1 and subtype ayw2. Eight samples (group I) contained at least one mutation at the single amino acid level. Five out of 8 samples showed ALT levels above the normal range of which only one sample was anti-HBe positive. Group II (17 samples) did not contain any mutation, 4 were anti-HBe positive and 9 had increased ALT levels. In both groups, in anti-HBe positive patients who showed high levels of ALT, only one sample had amino acid mutations. Conversely, 7 of 20 samples with HBeAg positivity had mutations. In both groups, from a total of 18 amino acid mutations, 5 (27.5%) and 13 (72.5%) occurred in anti-HBe and HBeAg positive groups respectively. In general, there was no correlation between the occurrence of mutations and HBeAg status/ALT levels of the patients. Conclusion: The relatively small number of nucleotide/amino acid mutations might belong to either the initial phase (tolerant phase) of chronicity in our patients, regardless of being anti-HBe positive or that even in anti-HBe positive phase in Iranian genotype D-infected patients, a somehow tolerant pattern due to the host genetic factors may be responsible.
Atefeh Yari, Taravat Bamdad, Hoorieh Soleimanjahi, Ala Habibian, Seyed Mahmood Seyed Khorrami,
Volume 15, Issue 1 (6-2021)
Abstract
One of the major concerns in the world is the Coronavirus Disease 2019 (COVID-19), an infectious disease caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). Although the knowledge is limited about the risk factors for the disease, morbidity and mortality may increase in the patients with some underlying conditions such as cardiovascular disease, hypertension, diabetes, cancer, etc. These diseases can weaken the immune system and affect the body's ability to respond to infectious agents. Therefore, these patients are more at the risk for COVID-19 and also the underlying condition may worsen the severity of COVID-19 infection. On the other hand, SARS-CoV-2 via multiple pathophysiological mechanisms can lead to the progression of the underlying diseases and resulting in a poor outcome. The coronavirus binds to angiotensin-converting enzyme 2 (ACE2) which is expressed on the cells of many organs and it can directly affect tissues. Apoptosis of the cells may occur in patients with acute respiratory disease syndrome (ARDS) due to hypoxia in COVID-19. Moreover, SARS-CoV-2 leads to an imbalanced the immune inflammatory response in some patients which may cause indirectly organ injury. In this review we described the prevalence of COVID-19 in various underlying diseases and the impact of the SARS-CoV-2 in the outcome of these diseases. However, further studies are needed to investigate the prevalence of this new virus in patients with underlying diseases and its effects on the progression of illness.
Reihaneh Kazemi, mohammad Reza Aghasadeghi, Aras Rafiee, Fatemeh Motevalli, Mojtaba Hamidi-Fard,
Volume 16, Issue 1 (6-2022)
Abstract
Background and Aims: The main role of ncRNAs (non-coding RNAs) is to regulate various cellular activities. LncRNAs (long non-coding RNAs) are a group of ncRNAs that are over 200 base pairs in length. It has been shown that lncRNAs regulate and control various cellular functions. Disruption of the expression of lncRNAs can cause various disease and deficiency in the cell function. LncRNA-HULK is one of lncRNA, which is greatly increased in liver disorders, including hepatitis C. Recently, the use of HULK as a biomarker has been suggested as a prognostic factor for liver disease such as hepatocellular carcinoma. Therefore, this study aimed to investigate the level of lncRNA-Hulk in chronic HCV-infected patients.
Materials and Methods: The present study included 50 patients with chronic hepatitis C. After transferring the samples, total RNA was extracted and the quantity of HCV-RNA and lncRNA-HULK were determined using the real-time PCR assay. Finally, the relationship between HCV-RNA and lncRNA-HULK levels was evaluated.
Results: Of the total patients, 13 were female and 37 were male. All patients were HIV Ag/Ab and HBs Ag negative. Results showed that HCV-RNA level was 4,500-2,300,000 copies per mL of plasma. In addition, threshold cycles of lncRNA-HULK were calculated 28-38. Statistical analyses showed that there was a significant relationship between HCV-RNA level and lncRNA-HULK in the plasma of chronic patients.
Conclusion: In the recent study, the relationship between HCV-RNA quantity and lncRNA-HULC level in chronic hepatitis C patients was investigated. It is suggested that lncRNA-HULC levels could be considered as a biomarker in such patients. Accordingly, lncRNA-HULC quantification could be utilized to predict the progression of liver disease and the outcome in chronic HCV-infected patients.
|
|
.jpeg)
